Latest update on immunotherapy of Epstein-Barr virus-associated post-transplantation lymphoproliferative disease / 中国当代儿科杂志
Chinese Journal of Contemporary Pediatrics
; (12): 795-799, 2013.
Article
in Zh
| WPRIM
| ID: wpr-345704
Responsible library:
WPRO
ABSTRACT
Epstein-Barr virus (EBV)-associated post-transplantation lymphoproliferative disease (EBV-PTLD) is a potentially life-threatening complication after hematopoietic stem cell transplantation or solid organ transplantation. In the last decade, the survival of patients with EBV-PTLD has been significantly improved by immunotherapeutic interventions among high-risk patients. The immunotherapeutic interventions for EBV-PTLD include reduction in immunosuppression, CD20 monoclonal antibodies (rituximab) as monotherapy or in combination with chemotherapy, and adoptive immunotherapy with EBV-specific T cells. This paper reviews the latest update on the high-risk factors, clinical manifestations and immunotherapy of EBV-PTLD.
Full text:
1
Database:
WPRIM
Main subject:
Postoperative Complications
/
Therapeutics
/
Risk Factors
/
Hematopoietic Stem Cell Transplantation
/
Epstein-Barr Virus Infections
/
Immunotherapy
/
Lymphoproliferative Disorders
/
Methods
Type of study:
Etiology_studies
/
Risk_factors_studies
Limits:
Humans
Language:
Zh
Journal:
Chinese Journal of Contemporary Pediatrics
Year:
2013
Document type:
Article